Best Pharma Penny Stocks List Under ₹50

A strong pharmaceutical industry is essential for any nation to develop its economy as it has a direct impact on the productivity of the working population. Strong research and development facilities help manufacture medicines in a timely manner, preventing or minimizing the impact of pandemics. Pharma penny stocks in India offer huge investment opportunities due to the booming pharmaceutical industry. The penny stocks generally trade at a price below ₹50, and substantial returns can be generated if the companies deliver strong financial results through innovation, global expansion, and regulatory approvals.

In this blog, we look at some of the best pharma penny stocks in India and discuss the advantages and risks of investing in them.

Understanding Penny Pharma Stocks 

Penny pharma stocks are shares of small pharmaceutical companies that generally trade below ₹50. The stocks of these companies carry great promise for enormous growth, but volatility and risk associated with them are high as well. Pharma penny stocks offer the potential for high returns if the company expands its product offerings, invests in research and development and increases its market share. However, investors must be aware of the competitive and research-intensive nature of the pharmaceutical industry, which makes it difficult for small pharmaceutical companies to maintain consistent profitability.

As the pharmaceutical sector in India develops, smaller companies are increasingly filling the gaps for region-specific and national healthcare needs. Most of these pharmaceutical penny stocks are issued by companies that have sound business models, experienced management teams, and an increasingly growing market presence. They can be an ideal investment for investors with high-risk tolerance.

List of Pharma Penny Stocks in India 2024 – Under ₹50

TOP 5 Pharma Penny Stocks in India 2024 – An Overview

Let us see the best pharma penny stocks in India, why to invest in them, and what makes them so special.

1. Syncom Formulations (India) Ltd.

Syncom Formulations was established in 1995 and currently has two business divisions, i.e. an international division and a domestic division. The company’s operations in both the domestic as well as international markets generate consistent revenues it needs to reinvest for further R&D. Key features of the company are:

• API and Formulations: Syncom Formulations produces large quantities of APIs and formulations in the form of anti-malarial, anti-bacterial, and cardiovascular drugs. The company currently has over 400 registered products.

• Exports to over 25 Countries: The company exports products to more than 25 countries, which helps increase its visibility and tap the global pharmaceutical markets.

• Quality Products: Syncom ensures high-quality standards in manufacturing and adheres to global regulatory compliance.

2. Nectar Lifesciences Ltd.

Nectar Lifesciences Ltd. was established in 1995 and is a leading global manufacturer of antibiotic medicines with export operations in over 45 countries. The company has 11 manufacturing facilities in India and a subsidiary in Portugal. Key features of the company are:

• Research and Development: The company boasts a robust R&D infrastructure that continues to work on the development of new formulations as well as the improvement of the existing ones.

• Regulatory Approvals: Nectar Lifesciences products have received regulatory approvals in 30 countries.

3. Medico Remedies Ltd.

Medico Remedies was established in 1994 and has its headquarters in Mumbai. The diversified product portfolio, from painkillers to anti-inflammatory medicines, caters to the growing demand for medicines. Key features of the company are:

• Broad Product Range: Medico Remedies produces a vast range of pharmaceutical formulations in antibiotic, anti-inflammatory, pain management, and many more categories.

• Increasing Indian and International Markets: Medico Remedies is rapidly expanding its footprints across the Indian market as well as in key international geographies.

• Strategic Tie-ups: Medico has collaborated with major global pharmaceutical companies that are helping the company increase its market share.

4. Lasa Supergenics Ltd.

Lasa Supergenics was incorporated in 2016 with a focus on developing active pharmaceutical ingredients (APIs) for animal healthcare and personal hygiene products such as hand sanitizers, anti-bacterial and antiseptic products. Unlike most pharmaceutical firms, Lasa Supergenics focuses on veterinary products. Its target market has long been underserved, which makes it the only player in this sector. Key features of the company are:  

• Animal Healthcare: The company focuses on manufacturing veterinary products, such as nutraceuticals, feed additives, and animal health care formulations.

• R&D/Innovation: The organization invests heavily in the R&D process to develop innovative veterinary products for both the domestic and international markets.

• International Demand: Lasa’s veterinary products have found a growing market in countries that are witnessing an increasing need for animal health products.

5. Ind-Swift Ltd.

Ind-Swift was established in 1986 in Chandigarh, India. The company has a strong customer base in Europe, the Middle East, and the US and a total prescribing doctor base of 2.5 lakhs. Joint ventures and subsidiaries in Iran, Singapore, and Dubai indicate the company’s strong global presence. The key features of the company are:

• Diverse Product Line: The company has a portfolio of about 750 products in therapeutic categories such as cardiology, diabetology, oncology, neurology, etc.

• Expanding Global Presence: Export operations in over 50 countries help the company maintain stable revenue streams, as well as its market share.

• Strong Financial Track Record: Ind-Swift has a strong financial track record that supports this company’s reliability in the face of stiff industry competition.

Advantages of Investing in Pharma Penny Stocks

The advantages of investing in pharma penny stocks are:

• High Growth Potential: Pharma penny stocks often represent small companies that are in their early growth stage. Such companies can offer significant returns.

• Affordable Investment Option: Trading at a low price, usually below ₹50, these penny stocks can be bought by anyone. Due to their low prices, investors can easily diversify their portfolios across multiple stocks within a limited budget.

• Emerging Sectors Exposure: Some pharma penny stocks are operating in niche or emerging sectors such as biotechnology, animal healthcare, etc. Investing in such companies can provide early access to an untapped market.

• Undervalued Opportunities: These stocks, at times, are undervalued because they are relatively lesser-known. An opportunity exists to invest in potential companies before they gain much wider market recognition.

• Diversification of Portfolio: Adding pharma penny stocks to a portfolio can help an investor gain exposure to this fast-growing pharmaceutical and healthcare industry by diversifying risks across different sectors.

Risks in Pharma Penny Stocks

The risks of investing in pharma penny stocks are:

• High Volatility: Penny stocks are volatile, which can lead to losses for investors.

• Regulatory Risks: Companies involved in pharmaceutical businesses must fulfil strict regulatory requirements. Regulatory approvals can be delayed or denied, which can affect the share price negatively.

• Low Liquidity: These shares usually have low volumes; hence, it is challenging for investors to sell or purchase in large quantities without influencing the share price.

• Price Manipulation: Pharma penny stocks are vulnerable to manipulation due to their small market capitalization and low prices, increasing risks for retail investors.

Conclusion

Pharma penny stocks can be an attractive investment opportunity for individuals who are willing to take higher risks in exchange for big returns. Most of the companies mentioned above have strong R&D capabilities, international operations, and diverse product portfolios. These stocks can be considered for investment due to their long-term growth potential, which is supported by India’s fast-growing pharmaceutical industry. Investors looking to invest in these stocks should conduct a thorough search and keep track of market trends for better decision-making. It is advised to consult a financial advisor before investing.

Frequently Asked Questions (FAQs)